StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Research analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Trevena in a report on Thursday, November 14th.

Trevena Trading Down 1.4 %

NASDAQ:TRVN opened at $1.76 on Friday. The firm’s fifty day simple moving average is $1.80 and its 200 day simple moving average is $4.15. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23. The firm has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million during the quarter. On average, analysts predict that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.